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Dear Dr. Karlan,
We enjoyed reading the recent meta-analysis by Verdoodt et al.
(2016), which summarized the associations between non-steroidal
anti-inﬂammatory drugs (NSAIDs) and endometrial cancer risk in
epidemiologic studies. We applaud the authors for a comprehensive
analysis and for examining associations stratiﬁed by NSAID type and
study design, and for additionally examining the potential for differ-
ences between population- and hospital-based case–control studies.
We outline below a few minor concerns with an otherwise excellent
article.
We have contributed two studies to the Verdoodt et al. analysis. In
the Vitamins And Lifestyle (VITAL) cohort (Brasky et al., 2013), regular
NSAID use was deﬁned as use of individual medications (i.e., aspirin,
ibuprofen, naproxen, and COX-2 inhibitors) ≥1 day/week for ≥1 year.
The results from our work in the VITAL cohort (n = 262 cases) were
suggestive of an inverse association between aspirin and endometrial
cancer incidence: low use (b4 days/week or b4 years) was associated
with a 23% reduction in risk (HR 0.77, 95% CI: 0.54–1.09), and high
use (≥4 days/week and ≥4 years) was associated with 36% reductions
in risk (HR 0.64, 95% CI: 0.41–1.01). The trend across categories was
P b 0.03. We believe that Verdoodt et al. chose the incorrect point
estimate to reﬂect associations in this cohort in a manner comparable
to others in the analysis. The authors chose to include the HR corre-
sponding to low use (i.e., HR 0.77, referenced above) in their analytic
Table 3 and forest plot in Figure 1. Their reasoning for this choice was
not speciﬁed. The association between any aspirin use (i.e., low and
high use) relative to non-use and endometrial cancer risk, as reported
in the manuscript text was in fact both inverse and statistically
signiﬁcant (HR 0.72, 95% CI: 0.53–0.98). Using a random effects model
in STATA, we performed ameta-analysis of aspirin use and endometrial
cancer risk among the prospective studies included in the Verdoodt
et al. paper. We substituted for the VITAL cohort the HR and 95% CI
for any aspirin use. The result of our meta-analysis was a pooled
RR of 0.91 (95% CI: 0.83–0.99). The P value was 0.03. Although the
difference between these results is indeed very small, we note – for
better or for worse – the strong reliance of Gynecologic Oncology's
readership upon statistical signiﬁcance, and thus the slight difference
in interpretation of Verdoodt et al.'s primary ﬁndingmay bemeaningful
in this context.
In a subsequent analysis among postmenopausal women participat-
ing in theWomen's Health Initiative (WHI), we did not observe an asso-
ciation between consistent intakes of NSAIDs (overall or by medication
type) with endometrial cancer risk (Brasky et al., 2014). Given that
intakes recorded in the WHI reﬂected use over the prior two weeks
(and despite our efforts to mitigate the error by combining NSAID
data from baseline with that from a follow-up questionnaire), it wouldhttp://dx.doi.org/10.1016/j.gore.2016.04.007
2352-5789/© 2016 The Authors. Published by Elsevier Inc. This is an open access article undernot be surprising to anticipate that any but the strongest associations
might be masked by measurement error. This error is easily demon-
strated in colorectal cancer, where an inverse association is well
established: we reported no association between inconsistent NSAID
use (deﬁned as NSAID use at baseline or the year 3 follow-up) and colo-
rectal cancer risk relative to no NSAID use at either time point (HR 1.00,
95% CI: 0.86–1.17), but observed inverse associations with colorectal
cancer risk for consistent NSAID use (i.e., use of NSAIDs at both baseline
and year 3) (HR 0.78, 95% CI: 0.64–0.95), and signiﬁcant duration-de-
pendent trends among these users (P b 0.02). The discrepancy between
these ﬁndings emphasizes the challenge in examining NSAIDs in rela-
tion to cancer occurrence in most studies, regardless of design, and
highlights the continued and predominantly unmet need for strong
measurement ofmedication use that includes recency of use, frequency,
intensity (i.e., number of pills taken per pill-taking day), duration, and
dose.
Lastly, we would like to call the editor's attention to this and indeed
any meta-analysis that includes all papers examining associations be-
tween a given exposure and outcome without an a priori assessment
and analytic plan for studies of potentially poorer quality. The authors
included in themeta-analysis their recent assessment of low-dose aspi-
rin and non-aspirin NSAIDs, in an enormous case–control study using a
Danish prescription registry (Brøns et al., 2015). Unlike other studies in
the meta-analysis, regular-strength aspirin, sold primarily over the
counter in Denmark, was not assessed. Indeed, low-dose aspirin is not
thought to hold signiﬁcant anti-inﬂammatory properties (Vaucher et
al., 2014). Consistent with this hypothesis, in the VITAL cohort the
reduction in endometrial cancer risk from aspirin use was restricted to
regular-strength formulations. Unfortunately, only our studies in
VITAL and the WHI have separately examined low-dose and regular-
strength aspirin. The authors were also insufﬁciently able to assess
potential confounding by body mass or several other endometrial
cancer risk factors. Given this context, and the study's signiﬁcantweight
in themeta-analysis, it would have beenworthwhile to report summary
point estimates with and without its exclusion. Similarly, the study by
Schreinemachers et al. (Schreinemachers and Everson, 1994), also
lacked the capacity to assess or statistically adjust for potential
confounders aside from age.
Although we agree in principal that meta-analyses are useful for
summarizing associations across epidemiologic studies, the issues we
outline here highlight the challenge in performing such analyses, the
relative ease with which results from such analyses are beholden to
choices that investigators make in selecting results to summarize, and
the need to establish a strong degree of epidemiologic rigor to ensure
meaningful interpretation and dissemination of ﬁndings.
Best Regards,
Theodore M. Brasky
David E. Cohn
Brittany M. Bernardothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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